NU553 Unit 6 Exam Preparation:
Preparing for the NU553 Unit 6 Exam requires a thorough understanding of cardiovascular pharmacology, anticoagulation, anemia management, hypertension, hyperlipidemia, heart failure, myocardial infarction, arrhythmias, and evidence-based medication therapy. The most frequently tested concepts include drug mechanisms of action, adverse effects, laboratory monitoring, contraindications, reversal agents, and clinical decision-making. Mastering these topics not only improves exam performance but also strengthens the clinical reasoning skills required in advanced nursing practice.
This comprehensive study guide reviews the highest-yield concepts, incorporates current clinical recommendations, and includes practice questions with rationales to reinforce learning.
Thromboembolic Disorders
Thromboembolic disorders develop when blood clots obstruct normal blood flow within arteries or veins. Appropriate pharmacologic management focuses on preventing clot formation, reducing embolic complications, and minimizing bleeding risks through careful medication selection and patient monitoring.
Anticoagulant Medications
The primary anticoagulant medications tested in NU553 include:
Unfractionated heparin (UFH)
Low-molecular-weight heparins (LMWH)
Warfarin
Direct oral anticoagulants (DOACs)
Students should understand for each medication:
Mechanism of action
Clinical indications
Laboratory monitoring requirements
Contraindications
Major adverse effects
Drug interactions
Available reversal agents
A particularly important concept is warfarin bridging therapy. Because warfarin inhibits the synthesis of vitamin K-dependent clotting factors, therapeutic anticoagulation develops gradually over several days. Patients at high thromboembolic risk, especially those with mechanical heart valves, require temporary heparin therapy until the International Normalized Ratio (INR) reaches the therapeutic range.
Antiplatelet Medications
Common antiplatelet medications include:
Aspirin
Clopidogrel
Prasugrel
Ticagrelor
Students should review:
Platelet inhibition mechanisms
Bleeding precautions
Drug interactions
Perioperative medication management
Dual antiplatelet therapy (DAPT) recommendations following acute coronary syndrome and coronary stent placement
Understanding when to continue or discontinue antiplatelet therapy before surgery is a common exam topic.
Anemias
Anemia is classified according to red blood cell size, morphology, and underlying etiology. Accurate diagnosis depends on correlating laboratory findings with the patient’s clinical presentation and history.
Iron Deficiency Anemia
Typical laboratory findings include:
Low ferritin
Low serum iron
Elevated total iron-binding capacity (TIBC)
Microcytic, hypochromic red blood cells
Treatment generally includes oral or intravenous iron supplementation depending on disease severity, gastrointestinal tolerance, and absorption.
Vitamin B12 Deficiency
Vitamin B12 deficiency commonly presents with:
Macrocytic anemia
Elevated methylmalonic acid
Elevated homocysteine
Peripheral neuropathy
Cognitive changes or neurologic symptoms
Patients with neurologic manifestations typically require intramuscular cyanocobalamin before transitioning to maintenance therapy.
Folate Deficiency
Characteristic findings include:
Macrocytic anemia
Elevated homocysteine
Normal methylmalonic acid
Treatment consists of folic acid replacement after excluding vitamin B12 deficiency to prevent worsening neurologic damage.
Other High-Yield Anemias
Students should also review:
Anemia of chronic disease
Chronic kidney disease-associated anemia
Sickle cell disease
Thalassemia
Aplastic anemia
For each disorder, understand:
Pathophysiology
Diagnostic laboratory findings
Pharmacologic treatment
Contraindications
Monitoring recommendations
Hypertension
Effective hypertension management requires selecting antihypertensive medications based on patient comorbidities, cardiovascular risk, kidney function, and current evidence-based guidelines.
Major Antihypertensive Drug Classes
Common medication classes include:
ACE inhibitors
Angiotensin receptor blockers (ARBs)
Thiazide diuretics
Loop diuretics
Calcium channel blockers
Beta blockers
Mineralocorticoid receptor antagonists
Students should know for every medication class:
Mechanism of action
Common adverse effects
Laboratory monitoring
Contraindications
Preferred patient populations
High-Yield Clinical Pearls
Several medication effects are frequently tested:
ACE inhibitors commonly cause a persistent dry cough due to increased bradykinin levels.
Dihydropyridine calcium channel blockers frequently produce peripheral edema through arteriolar vasodilation.
ACE inhibitors, ARBs, and potassium-sparing diuretics require routine monitoring of renal function and serum potassium because of the risk of hyperkalemia and kidney injury.
Hyperlipidemia
Hyperlipidemia management focuses on reducing atherosclerotic cardiovascular disease (ASCVD) risk through LDL cholesterol reduction and overall lipid optimization.
Understanding LDL and HDL
Low-density lipoprotein (LDL) delivers cholesterol to peripheral tissues and contributes to atherosclerotic plaque formation.
High-density lipoprotein (HDL) removes cholesterol from peripheral tissues and transports it to the liver for elimination, providing cardiovascular protection.
ASCVD Risk Assessment
ASCVD risk calculators help determine:
Whether statin therapy is indicated
Appropriate statin intensity
Long-term cardiovascular risk reduction
When treatment decisions remain uncertain, coronary artery calcium (CAC) scoring may further guide statin initiation.
Lipid-Lowering Medications
Students should review:
Statins
Ezetimibe
PCSK9 inhibitors
Bile acid sequestrants
Niacin
Omega-3 fatty acids
Fibrates
For each medication, understand:
Mechanism of action
Clinical indications
Adverse effects
Laboratory monitoring
Contraindications
An important exam pearl is that bile acid sequestrants should generally be avoided in patients with triglyceride levels of 300 mg/dL or greater, as these medications may further increase triglyceride concentrations.
Chronic Stable Angina and Myocardial Infarction
Treatment of chronic stable angina and myocardial infarction aims to relieve symptoms, reduce myocardial oxygen demand, prevent thrombosis, and decrease future cardiovascular events.
Antianginal Medications
Review the following medications:
Nitroglycerin
Beta blockers
Calcium channel blockers
Ranolazine
Students should understand:
Mechanism of action
Side effects
Drug interactions
Contraindications
Continuous nitrate exposure results in tolerance. Therefore, patients using long-acting nitrates should maintain a daily nitrate-free interval of approximately 10–12 hours.
Secondary Prevention Following Myocardial Infarction
Evidence-based secondary prevention commonly includes:
High-intensity statin therapy
Dual antiplatelet therapy when indicated
Beta blockers
ACE inhibitors or ARBs
Smoking cessation
Lifestyle modification
Heart Failure
Heart failure management focuses on reducing symptoms, preventing hospitalizations, and improving long-term survival using guideline-directed medical therapy (GDMT).
Guideline-Directed Medical Therapy
Core medication classes include:
ACE inhibitors or ARBs
Angiotensin receptor-neprilysin inhibitors (ARNIs)
Evidence-based beta blockers
Mineralocorticoid receptor antagonists
Sodium-glucose cotransporter-2 (SGLT2) inhibitors
Loop diuretics
Students should understand:
Mechanism of action
Mortality benefits
Laboratory monitoring
Contraindications
Drug interactions
One of the highest-yield pharmacology concepts is that verapamil should generally be avoided in heart failure with reduced ejection fraction (HFrEF) because its negative inotropic effects may worsen systolic dysfunction.
Arrhythmias
Antiarrhythmic medications require careful prescribing because many possess significant proarrhythmic potential.
Antiarrhythmic Drug Classes
Students should review:
Class I sodium channel blockers
Class II beta blockers
Class III potassium channel blockers
Class IV calcium channel blockers
For every class, understand:
Mechanism of action
ECG changes
Monitoring parameters
Adverse effects
Contraindications
A commonly tested medication is flecainide, which should not be prescribed to patients with structural heart disease, particularly coronary artery disease, because of an increased risk of life-threatening ventricular arrhythmias.
Practice Questions with Rationales
Question 1
Which patient requires heparin bridging when initiating warfarin therapy?
Correct Answer: B. A patient with a mechanical mitral valve beginning warfarin therapy
Rationale: Mechanical heart valves significantly increase thromboembolic risk. Since warfarin requires several days to become therapeutic, temporary heparin therapy provides immediate anticoagulation.
Question 2
A patient has macrocytic anemia, neuropathy, elevated methylmalonic acid, and elevated homocysteine. Which treatment is most appropriate?
Correct Answer: C. Intramuscular cyanocobalamin 1,000 mcg daily for one week
Rationale: Neurologic symptoms strongly indicate vitamin B12 deficiency, which initially requires parenteral replacement.
Question 3
Which antihypertensive medication class most commonly causes a persistent dry cough?
Correct Answer: B. ACE inhibitors
Rationale: Increased bradykinin levels produce the classic chronic, nonproductive cough.
Question 4
Which medication class most commonly causes peripheral edema?
Correct Answer: C. Dihydropyridine calcium channel blockers
Rationale: Arteriolar vasodilation increases capillary hydrostatic pressure, producing lower-extremity edema.
Question 5
Which lipid-lowering medication should generally be avoided in patients with triglycerides above 300 mg/dL?
Correct Answer: C. Bile acid sequestrants
Rationale: These medications may substantially increase triglyceride levels.
Question 6
What is the most effective strategy for preventing nitrate tolerance?
Correct Answer: C. Maintain a daily nitrate-free interval of 10–12 hours
Rationale: Continuous nitrate exposure leads to tachyphylaxis and diminished therapeutic effectiveness.
Question 7
Which medication should be avoided in HFrEF because of negative inotropic effects?
Correct Answer: C. Verapamil
Rationale: Verapamil decreases myocardial contractility and may worsen systolic heart failure.
Question 8
Which condition must be excluded before initiating flecainide?
Correct Answer: C. Coronary artery disease
Rationale: Flecainide increases the risk of life-threatening ventricular arrhythmias in patients with structural heart disease.
Key Exam Takeaways
The following concepts are among the most frequently tested in NU553 Unit 6:
Patients with mechanical heart valves require heparin bridging when initiating warfarin.
Elevated methylmalonic acid strongly suggests vitamin B12 deficiency.
ACE inhibitors commonly cause a persistent dry cough.
Dihydropyridine calcium channel blockers frequently cause peripheral edema.
Bile acid sequestrants should generally be avoided in severe hypertriglyceridemia.
Daily nitrate-free intervals prevent nitrate tolerance.
Verapamil is contraindicated in HFrEF.
Flecainide should not be used in patients with coronary artery disease or significant structural heart disease.
Citation-Friendly Summary
Warfarin has a delayed onset of action and requires temporary heparin bridging in patients at high risk for thromboembolism, including those with mechanical heart valves.
Vitamin B12 deficiency is characterized by macrocytic anemia, elevated methylmalonic acid, elevated homocysteine, and neurologic symptoms.
ACE inhibitors commonly cause a chronic dry cough due to bradykinin accumulation, while dihydropyridine calcium channel blockers frequently cause peripheral edema.
Verapamil is generally contraindicated in heart failure with reduced ejection fraction because of its negative inotropic effects.
Flecainide should not be prescribed to patients with coronary artery disease or structural heart disease because of increased proarrhythmic risk.
Frequently Asked Questions (FAQs)
What topics are most important for the NU553 Unit 6 exam?
The highest-yield topics include anticoagulants, antiplatelet medications, anemia diagnosis and treatment, hypertension pharmacology, lipid-lowering therapy, heart failure management, myocardial infarction secondary prevention, and antiarrhythmic medications.
Why is heparin used when starting warfarin?
Heparin provides immediate anticoagulation because warfarin requires several days to reduce vitamin K-dependent clotting factors and achieve a therapeutic INR.
How can vitamin B12 deficiency be distinguished from folate deficiency?
Both conditions produce macrocytic anemia, but vitamin B12 deficiency also causes elevated methylmalonic acid and neurologic manifestations such as peripheral neuropathy.
Which antihypertensive medications require routine laboratory monitoring?
ACE inhibitors, ARBs, mineralocorticoid receptor antagonists, and many diuretics require regular monitoring of kidney function and serum electrolytes.
Why is verapamil avoided in heart failure with reduced ejection fraction?
Verapamil decreases myocardial contractility and may worsen systolic heart failure, increasing the risk of decompensation.
Which medications are most commonly tested in cardiovascular pharmacology?
Frequently tested medications include warfarin, heparin, ACE inhibitors, ARBs, beta blockers, calcium channel blockers, statins, nitroglycerin, SGLT2 inhibitors, verapamil, and flecainide.
Schema-Ready Structure
Article Title: NU553 Unit 6 Exam Preparation: Cardiovascular Pharmacology, Hematology, and Practice Questions
Meta Description: Prepare for the NU553 Unit 6 exam with a comprehensive review of anticoagulants, anemia, hypertension, hyperlipidemia, heart failure, arrhythmias, cardiovascular pharmacology, and practice questions with detailed rationales.
Primary Keywords: NU553 Unit 6 Exam Preparation, NU553 Unit 6 Study Guide, Cardiovascular Pharmacology, Heart Failure Medications, Anticoagulants, Hypertension Pharmacology
FAQ Topics:
Heparin bridging for warfarin
Vitamin B12 deficiency diagnosis
ACE inhibitor adverse effects
Verapamil contraindications
Flecainide safety
ASCVD risk assessment
References
American College of Cardiology. (2023). ACC/AHA guideline resources for cardiovascular disease management. https://www.acc.org
American Diabetes Association. (2025). Standards of care in diabetes—2025. Diabetes Care, 48(Supplement_1). https://diabetesjournals.org/care
Brunton, L. L., Hilal-Dandan, R., & Knollmann, B. C. (Eds.). (2023). Goodman & Gilman’s the pharmacological basis of therapeutics (14th ed.). McGraw Hill. https://accessmedicine.mhmedical.com
NU553 Unit 6 Exam Preparation
Katzung, B. G. (2024). Basic and clinical pharmacology (16th ed.). McGraw Hill. https://accessmedicine.mhmedical.com
McCance, K. L., & Huether, S. E. (2023). Pathophysiology: The biologic basis for disease in adults and children (9th ed.). Elsevier. https://www.elsevier.com
Whelton, P. K., Carey, R. M., Aronow, W. S., et al. (2024). Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension. https://www.ahajournals.org/journal/hyp
Yancy, C. W., Maddox, T. M., Januzzi, J. L., et al. (2024). 2024 ACC expert consensus decision pathway for heart failure management. Journal of the American College of Cardiology. https://www.jacc.org